Search
Propranolol
go.drugbank.com/drugs/DB00571ApprovedInvestigationalPropranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. … [L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, P-glycoprotein inhibitorsProducts: PROPRANOLOL AL 40, PROPRANOLOL AL 80Naproxen
go.drugbank.com/drugs/DB00788ApprovedInvestigationalVet approved[A178975] It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. … Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994.
Mixtures: Aleve PM, Naproxen PMCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. … [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Ag-letrozole, Ag-letrozole TabletsExemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: EXEMESTAN AL 25 MGAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. … [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalTislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsAmoxicillin
go.drugbank.com/drugs/DB01060ApprovedInvestigationalVet approvedAmoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972.
Synonyms: AX, p-HydroxyampicillinMixtures: AMOXICILLINA E ACIDO CLAVULANICO P-CARE, AMOXICILLINA E ACIDO CLAVULANICO P-CAREVinorelbine
go.drugbank.com/drugs/DB00361ApprovedInvestigationalIt is a third-generation vinca alkaloid. … A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: Aj-vinorelbine, RENOVEL 10 MG/1 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigational[A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. … Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide